Deutsch English Français

Contact

EP2706982

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2706982

EP2706982 - INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE [Right-click to bookmark this link]
Status	Patent maintained as amended Status updated on 05.02.2021 Database last updated on 25.09.2024
Former	The patent has been granted Status updated on 01.12.2017
Former	Grant of patent is intended Status updated on 01.08.2017
Most recent event Tooltip	10.11.2023	Lapse of the patent in a contracting state New state(s): AL	published on 13.12.2023 [2023/50]
Applicant(s)	For all designated states EURO-CELTIQUE S.A. 1, rue Jean Piret 2350 Luxembourg / LU
	[2016/26]
Former [2014/12]	For all designated states Euro-Celtique S.A. 2, avenue Charles de Gaulle 1653 Luxembourg / LU
Inventor(s)	01 / STRANG, John c/o National Addiction Centre Addiction Sciences Building 4 Windsor Walk Denmark Hill London SE5 8AF / GB
	02 / OKSCHE, Alexander c/o Mundipharma GmbH Mundipharma Straße 2 65549 Limburg / DE
	03 / HARRIS, Stephen c/o Purdue Pharma L. P. One Stamford Forum 201 Tresser Boulevard Stamford Connecticut 06901-3431 / US
	04 / SMITH, Kevin c/o Mundipharma Research Limited Cambridge Science Park Milton Road Cambridge CB4 0GW / GB
	05 / MOTTIER, Lucie Helene Jeanne c/o Mundipharma Research Limited Cambridge Science Park Milton Road Cambridge CB4 0GW / GB
	[2014/12]
Representative(s)	Ledl, Andreas Maiwald GmbH Elisenhof Elisenstraße 3 80335 München / DE
	[N/P]
Former [2021/10]	Ledl, Andreas Maiwald Patentanwalts- und Rechtsanwaltsgesellschaft mbH Elisenhof Elisenstraße 3 80335 München / DE
Former [2014/12]	Ledl, Andreas Maiwald Patentanwalts GmbH Elisenhof Elisenstraße 3 80335 München / DE
Application number, filing date	12721507.7	11.05.2012
	[2018/01]
	WO2012EP58792
Priority number, date	EP20110166076	13.05.2011 Original published format: EP 11166076
	[2014/12]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2012156317
	Date:	22.11.2012
	Language:	EN
	[2012/47]
	Type:	A2 Application without search report
	No.:	EP2706982
	Date:	19.03.2014
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 22.11.2012 takes the place of the publication of the European patent application.
	[2014/12]
	Type:	B1 Patent specification
	No.:	EP2706982
	Date:	03.01.2018
	Language:	EN
	[2018/01]
	Type:	B2 New European patent specification
	No.:	EP2706982
	Date:	10.03.2021
	Language:	EN
	[2021/10]
Search report(s)	International search report - published on:	EP	10.05.2013
Classification	IPC:	A61K9/00, A61K31/135, A61K9/08, A61P25/36	[2014/12]
	CPC:	A61K31/485 (EP,AT,CN,IL,KR,RU,US); A61K9/0043 (AT,CN,IL,KR,RU,US); A61K47/02 (IL,RU,US); A61K9/0019 (IL,US); A61K9/08 (AT,IL,RU); A61K9/12 (CN,IL); (+) A61P11/00 (EP,IL); A61P25/00 (EP,IL); A61P25/04 (EP,IL); A61P25/36 (EP,IL); A61P39/02 (EP,IL); A61P43/00 (EP,IL) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/12]
Extension states	BA	12.12.2013
	ME	12.12.2013
Title	German:	INTRANASALE PHARMAZEUTISCHE DARREICHUNGSFORMEN MIT NALOXON	[2014/12]
	English:	INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE	[2014/12]
	French:	FORMES DOSIFIÉES PHARMACEUTIQUES INTRANASALES COMPRENANT DE LA NALOXONE	[2014/12]
Entry into regional phase	12.12.2013	National basic fee paid
	12.12.2013	Designation fee(s) paid
	12.12.2013	Examination fee paid
Examination procedure	12.12.2013	Examination requested [2014/12]
	01.07.2014	Amendment by applicant (claims and/or description)
	08.12.2015	Observations by third parties
	08.03.2016	Despatch of a communication from the examining division (Time limit: M06)
	19.09.2016	Reply to a communication from the examining division
	01.03.2017	Observations by third parties
	27.06.2017	Date of oral proceedings
	28.07.2017	Minutes of oral proceedings despatched
	02.08.2017	Communication of intention to grant the patent
	21.11.2017	Fee for grant paid
	21.11.2017	Fee for publishing/printing paid
	21.11.2017	Receipt of the translation of the claim(s)
Divisional application(s)	EP17208976.5 / EP3320893
	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 08.03.2016
Opposition(s)	Opponent(s)	01 01.10.2018 20.11.2019 WITHDRAWN Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB Opponent's representative Booth, Catherine Louise Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG / GB
		[2021/10]
	Former [2019/52]
	Opponent(s)	01 01.10.2018 20.11.2019 WITHDRAWN Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG / GB Opponent's representative Booth, Catherine Louise Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB
	Former [2018/45]
	Opponent(s)	01 01.10.2018 WITHDRAWN Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB Opponent's representative Booth, Catherine Louise Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB
	10.10.2018	Invitation to proprietor to file observations on the notice of opposition
	27.02.2019	Reply of patent proprietor to notice(s) of opposition
	26.05.2020	Cancellation of oral proceeding that was planned for 09.06.2020
	09.06.2020	Date of oral proceedings
	09.07.2020	Despatch of interlocutory decision in opposition
	19.07.2020	Legal effect of interlocutory decision in opposition
	30.10.2020	Despatch of communication that the patent will be maintained as amended
	02.02.2021	Fee for printing new specification paid
Fees paid	Renewal fee
	27.05.2014	Renewal fee patent year 03
	28.05.2015	Renewal fee patent year 04
	30.05.2016	Renewal fee patent year 05
	30.05.2017	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	AL	11.05.2020
	CY	11.05.2020
	HR	11.05.2020
	LT	11.05.2020
	LU	11.05.2020
	LV	11.05.2020
	MT	11.05.2020
	RO	11.05.2020
	RS	11.05.2020
	SK	11.05.2020
	TR	11.05.2020
	HU	12.05.2020
	SI	12.05.2020
	MC	02.06.2020
	BG	30.11.2020
	SM	03.12.2020
	[2023/50]
Former [2022/30]	CY	11.05.2020
	HR	11.05.2020
	LT	11.05.2020
	LU	11.05.2020
	LV	11.05.2020
	MT	11.05.2020
	RO	11.05.2020
	RS	11.05.2020
	SK	11.05.2020
	TR	11.05.2020
	HU	12.05.2020
	SI	12.05.2020
	MC	02.06.2020
	BG	30.11.2020
	SM	03.12.2020
Former [2021/36]	CY	11.05.2020
	HR	11.05.2020
	LT	11.05.2020
	LU	11.05.2020
	LV	11.05.2020
	RO	11.05.2020
	RS	11.05.2020
	SK	11.05.2020
	HU	12.05.2020
	SI	12.05.2020
	MC	02.06.2020
	BG	30.11.2020
	SM	03.12.2020
Former [2021/15]	CY	11.05.2020
	HR	11.05.2020
	LT	11.05.2020
	LU	11.05.2020
	LV	11.05.2020
	RO	11.05.2020
	RS	11.05.2020
	SK	11.05.2020
	HU	12.05.2020
	MC	02.06.2020
	BG	30.11.2020
	SM	03.12.2020
	GR	09.12.2020
Former [2021/10]	CY	11.05.2020
	HR	11.05.2020
	LT	11.05.2020
	LV	11.05.2020
	RO	11.05.2020
	RS	11.05.2020
	SK	11.05.2020
	HU	12.05.2020
	MC	02.06.2020
	BG	30.11.2020
	SM	03.12.2020
	GR	09.12.2020
Former [2021/09]	CY	11.05.2020
	LT	11.05.2020
	RO	11.05.2020
	HU	12.05.2020
	MC	02.06.2020
	BG	30.11.2020
	SM	03.12.2020
	GR	09.12.2020
Former [2021/07]	LT	11.05.2020
Cited in	International search	[XI]WO8203768 (UNIV KENTUCKY [US]);
		[XI]WO0062757 (BRITANNIA PHARMACEUTICALS LTD [GB], et al);
		[XI]CN1575795 (TOXIC PHARMACEUTICS INST P L A [CN]);
	other	WO8203768
		WO0062757
		CN1575795
		US2006009447
	Opposition	WO8203768
		WO0062757
		CN1575795

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p